Trial Information
Current as of June 22, 2025
Completed
Keywords
ClinConnect Summary
Investigation of the effect of Grazax (ALK produced grass tablet) on asthma prevention in children with grass pollen allergy.
Children in the age of 6-12 years will be randomised to either placebo or Grazax treatment. Grazax has been approved for treatment of grass pollen allergy in adults and children, diagnosed with a positive skin prick test and/or specific immunoglobulin (IgE) test to grass pollen and with clinically relevant symptoms. This study will explore prevention of asthma in children with grass pollen induced allergy.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • A history of grass pollen allergy
- • Positive Skin prick test to grass
- • Positive specific IgE to grass
- Exclusion Criteria:
- • Asthma
About Alk Abelló A/S
ALK-Abelló A/S is a global biopharmaceutical company specializing in the development of innovative allergy immunotherapy treatments. With a strong commitment to improving patient outcomes, ALK focuses on research and development of products that address various allergic conditions, including asthma, rhinitis, and food allergies. Leveraging advanced scientific expertise and a robust pipeline of therapies, ALK aims to enhance the quality of life for individuals affected by allergies while adhering to the highest standards of safety and efficacy in clinical trial practices. The company is dedicated to advancing the field of allergy treatment through collaboration and innovation.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Turku, , Finland
Patients applied
Trial Officials
Erkka Valovirta, MD
Principal Investigator
Terveystalo Turku, Finland
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials